25 XP   0   0   10

Starpharma Holdings Ltd
Buy, Hold or Sell?

Let's analyse Starpharma together

PenkeI guess you are interested in Starpharma Holdings Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Starpharma Holdings Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Starpharma Holdings Ltd

I send you an email if I find something interesting about Starpharma Holdings Ltd.

Quick analysis of Starpharma (30 sec.)










What can you expect buying and holding a share of Starpharma? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
A$0.08
Expected worth in 1 year
A$-0.05
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.13
Return On Investment
-105.4%

For what price can you sell your share?

Current Price per Share
A$0.13
Expected price per share
A$0.12 - A$0.165
How sure are you?
50%

1. Valuation of Starpharma (5 min.)




Live pricePrice per Share (EOD)

A$0.13

Intrinsic Value Per Share

A$-0.35 - A$-0.31

Total Value Per Share

A$-0.27 - A$-0.23

2. Growth of Starpharma (5 min.)




Is Starpharma growing?

Current yearPrevious yearGrowGrow %
How rich?$22.3m$31m-$8.7m-39.0%

How much money is Starpharma making?

Current yearPrevious yearGrowGrow %
Making money-$10m-$10.3m$331.4k3.3%
Net Profit Margin-532.1%-345.0%--

How much money comes from the company's main activities?

3. Financial Health of Starpharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#580 / 1016

Most Revenue
#452 / 1016

Most Profit
#556 / 1016

Most Efficient
#756 / 1016

What can you expect buying and holding a share of Starpharma? (5 min.)

Welcome investor! Starpharma's management wants to use your money to grow the business. In return you get a share of Starpharma.

What can you expect buying and holding a share of Starpharma?

First you should know what it really means to hold a share of Starpharma. And how you can make/lose money.

Speculation

The Price per Share of Starpharma is A$0.125. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Starpharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Starpharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.08. Based on the TTM, the Book Value Change Per Share is A$-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Starpharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.02-19.5%-0.02-19.5%-0.03-20.1%-0.03-20.1%-0.02-17.3%
Usd Book Value Change Per Share-0.02-16.9%-0.02-16.9%-0.02-17.3%-0.01-4.6%0.00-1.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.0111.5%0.015.8%
Usd Total Gains Per Share-0.02-16.9%-0.02-16.9%-0.02-17.3%0.016.9%0.014.4%
Usd Price Per Share0.20-0.20-0.48-0.65-0.57-
Price to Earnings Ratio-8.17--8.17--18.88--25.83--18.31-
Price-to-Total Gains Ratio-9.41--9.41--21.92--23.35--8.37-
Price to Book Ratio3.67-3.67-6.30-9.57-8.25-
Price-to-Total Gains Ratio-9.41--9.41--21.92--23.35--8.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0802875
Number of shares12455
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.02-0.01
Usd Total Gains Per Share-0.020.01
Gains per Quarter (12455 shares)-263.62108.11
Gains per Year (12455 shares)-1,054.48432.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1054-1064719-287422
20-2109-21181438-574854
30-3163-31722158-8601286
40-4218-42262877-11471718
50-5272-52803596-14342150
60-6327-63344315-17212582
70-7381-73885034-20073014
80-8436-84425753-22943446
90-9490-94966473-25813878
100-10545-105507192-28684310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%2.021.01.08.3%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%11.013.00.045.8%
Dividend per Share0.00.01.00.0%1.00.02.033.3%1.00.04.020.0%1.00.09.010.0%1.00.023.04.2%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%11.013.00.045.8%

Fundamentals of Starpharma

About Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Fundamental data was last updated by Penke on 2024-04-03 19:11:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Starpharma Holdings Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Starpharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Net Profit Margin of -532.1% means that $-5.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Starpharma Holdings Ltd:

  • The MRQ is -532.1%. The company is making a huge loss. -2
  • The TTM is -532.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-532.1%TTM-532.1%0.0%
TTM-532.1%YOY-345.0%-187.1%
TTM-532.1%5Y-599.7%+67.6%
5Y-599.7%10Y-1,130.5%+530.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-532.1%-197.2%-334.9%
TTM-532.1%-210.4%-321.7%
YOY-345.0%-279.3%-65.7%
5Y-599.7%-436.8%-162.9%
10Y-1,130.5%-599.3%-531.2%
1.1.2. Return on Assets

Shows how efficient Starpharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • -30.0% Return on Assets means that Starpharma generated $-0.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Starpharma Holdings Ltd:

  • The MRQ is -30.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.0%TTM-30.0%0.0%
TTM-30.0%YOY-24.4%-5.6%
TTM-30.0%5Y-29.1%-1.0%
5Y-29.1%10Y-27.1%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.0%-13.6%-16.4%
TTM-30.0%-12.9%-17.1%
YOY-24.4%-11.9%-12.5%
5Y-29.1%-14.2%-14.9%
10Y-27.1%-16.2%-10.9%
1.1.3. Return on Equity

Shows how efficient Starpharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • -44.9% Return on Equity means Starpharma generated $-0.45 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Starpharma Holdings Ltd:

  • The MRQ is -44.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -44.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.9%TTM-44.9%0.0%
TTM-44.9%YOY-33.4%-11.5%
TTM-44.9%5Y-37.4%-7.5%
5Y-37.4%10Y-33.4%-4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.9%-17.0%-27.9%
TTM-44.9%-16.1%-28.8%
YOY-33.4%-15.4%-18.0%
5Y-37.4%-20.0%-17.4%
10Y-33.4%-21.1%-12.3%

1.2. Operating Efficiency of Starpharma Holdings Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Starpharma is operating .

  • Measures how much profit Starpharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • An Operating Margin of -839.5% means the company generated $-8.40  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Starpharma Holdings Ltd:

  • The MRQ is -839.5%. The company is operating very inefficient. -2
  • The TTM is -839.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-839.5%TTM-839.5%0.0%
TTM-839.5%YOY-510.4%-329.1%
TTM-839.5%5Y-849.1%+9.6%
5Y-849.1%10Y-1,333.1%+484.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-839.5%-286.1%-553.4%
TTM-839.5%-224.4%-615.1%
YOY-510.4%-288.4%-222.0%
5Y-849.1%-475.2%-373.9%
10Y-1,333.1%-624.7%-708.4%
1.2.2. Operating Ratio

Measures how efficient Starpharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.40 means that the operating costs are $9.40 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 9.395. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.395. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.395TTM9.3950.000
TTM9.395YOY6.104+3.291
TTM9.3955Y9.491-0.096
5Y9.49110Y15.490-5.999
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3952.997+6.398
TTM9.3953.247+6.148
YOY6.1043.766+2.338
5Y9.4915.675+3.816
10Y15.4907.857+7.633

1.3. Liquidity of Starpharma Holdings Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Starpharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.26 means the company has $3.26 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 3.256. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.256. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.256TTM3.2560.000
TTM3.256YOY5.929-2.673
TTM3.2565Y5.777-2.521
5Y5.77710Y6.978-1.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2563.930-0.674
TTM3.2564.251-0.995
YOY5.9295.436+0.493
5Y5.7776.045-0.268
10Y6.9786.363+0.615
1.3.2. Quick Ratio

Measures if Starpharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Quick Ratio of 3.00 means the company can pay off $3.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 3.000. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.000. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.000TTM3.0000.000
TTM3.000YOY5.645-2.645
TTM3.0005Y5.603-2.604
5Y5.60310Y6.876-1.273
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0003.629-0.629
TTM3.0004.065-1.065
YOY5.6455.397+0.248
5Y5.6035.993-0.390
10Y6.8766.277+0.599

1.4. Solvency of Starpharma Holdings Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Starpharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Starpharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that Starpharma assets are financed with 33.2% credit (debt) and the remaining percentage (100% - 33.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.332. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.332. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.332TTM0.3320.000
TTM0.332YOY0.269+0.063
TTM0.3325Y0.216+0.116
5Y0.21610Y0.168+0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3320.3320.000
TTM0.3320.334-0.002
YOY0.2690.268+0.001
5Y0.2160.366-0.150
10Y0.1680.390-0.222
1.4.2. Debt to Equity Ratio

Measures if Starpharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 49.6% means that company has $0.50 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.496. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.496. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.496TTM0.4960.000
TTM0.496YOY0.367+0.129
TTM0.4965Y0.288+0.208
5Y0.28810Y0.212+0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4960.381+0.115
TTM0.4960.390+0.106
YOY0.3670.334+0.033
5Y0.2880.434-0.146
10Y0.2120.466-0.254

2. Market Valuation of Starpharma Holdings Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Starpharma generates.

  • Above 15 is considered overpriced but always compare Starpharma to the Biotechnology industry mean.
  • A PE ratio of -8.17 means the investor is paying $-8.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -3.294. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.168. Based on the earnings, the company is expensive. -2
  • The TTM is -8.168. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.294MRQ-8.168+4.875
MRQ-8.168TTM-8.1680.000
TTM-8.168YOY-18.875+10.707
TTM-8.1685Y-25.831+17.663
5Y-25.83110Y-18.307-7.524
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.294-2.315-0.979
MRQ-8.168-2.560-5.608
TTM-8.168-2.664-5.504
YOY-18.875-4.122-14.753
5Y-25.831-6.258-19.573
10Y-18.307-6.108-12.199
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -3.639. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.024. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.024. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.639MRQ-9.024+5.386
MRQ-9.024TTM-9.0240.000
TTM-9.024YOY-21.781+12.756
TTM-9.0245Y-33.365+24.341
5Y-33.36510Y-28.906-4.459
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.639-3.067-0.572
MRQ-9.024-3.251-5.773
TTM-9.024-3.545-5.479
YOY-21.781-5.595-16.186
5Y-33.365-8.315-25.050
10Y-28.906-8.708-20.198
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Starpharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.67 means the investor is paying $3.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Starpharma Holdings Ltd:

  • The EOD is 1.479. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.669. Based on the equity, the company is fair priced.
  • The TTM is 3.669. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.479MRQ3.669-2.190
MRQ3.669TTM3.6690.000
TTM3.669YOY6.301-2.632
TTM3.6695Y9.575-5.906
5Y9.57510Y8.245+1.329
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4791.905-0.426
MRQ3.6692.111+1.558
TTM3.6692.095+1.574
YOY6.3012.836+3.465
5Y9.5753.443+6.132
10Y8.2453.794+4.451
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Starpharma Holdings Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Starpharma Holdings Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.033-0.0330%-0.034+2%-0.009-73%-0.003-92%
Book Value Per Share--0.0840.0840%0.117-28%0.106-21%0.110-23%
Current Ratio--3.2563.2560%5.929-45%5.777-44%6.978-53%
Debt To Asset Ratio--0.3320.3320%0.269+23%0.216+53%0.168+98%
Debt To Equity Ratio--0.4960.4960%0.367+35%0.288+72%0.212+134%
Dividend Per Share----0%-0%0.022-100%0.011-100%
Eps---0.038-0.0380%-0.039+3%-0.039+3%-0.034-11%
Free Cash Flow Per Share---0.034-0.0340%-0.034-1%-0.031-8%-0.033-5%
Free Cash Flow To Equity Per Share---0.036-0.0360%-0.026-27%-0.008-78%-0.008-77%
Gross Profit Margin--1.2081.2080%1.221-1%1.149+5%1.075+12%
Intrinsic Value_10Y_max---0.314--------
Intrinsic Value_10Y_min---0.355--------
Intrinsic Value_1Y_max---0.032--------
Intrinsic Value_1Y_min---0.035--------
Intrinsic Value_3Y_max---0.095--------
Intrinsic Value_3Y_min---0.107--------
Intrinsic Value_5Y_max---0.158--------
Intrinsic Value_5Y_min---0.179--------
Market Cap51505124.000-148%127732707.520127732707.5200%304910334.080-58%414513237.952-69%365892400.896-65%
Net Profit Margin---5.321-5.3210%-3.450-35%-5.997+13%-11.305+112%
Operating Margin---8.395-8.3950%-5.104-39%-8.491+1%-13.331+59%
Operating Ratio--9.3959.3950%6.104+54%9.491-1%15.490-39%
Pb Ratio1.479-148%3.6693.6690%6.301-42%9.575-62%8.245-56%
Pe Ratio-3.294+60%-8.168-8.1680%-18.875+131%-25.831+216%-18.307+124%
Price Per Share0.125-148%0.3100.3100%0.740-58%1.006-69%0.888-65%
Price To Free Cash Flow Ratio-3.639+60%-9.024-9.0240%-21.781+141%-33.365+270%-28.906+220%
Price To Total Gains Ratio-3.793+60%-9.407-9.4070%-21.925+133%-23.347+148%-8.367-11%
Quick Ratio--3.0003.0000%5.645-47%5.603-46%6.876-56%
Return On Assets---0.300-0.3000%-0.244-19%-0.291-3%-0.271-10%
Return On Equity---0.449-0.4490%-0.334-26%-0.374-17%-0.334-26%
Total Gains Per Share---0.033-0.0330%-0.034+2%0.014-344%0.009-486%
Usd Book Value--22361674.50022361674.5000%31082823.900-28%28162157.340-21%29123359.290-23%
Usd Book Value Change Per Share---0.021-0.0210%-0.022+2%-0.006-73%-0.002-92%
Usd Book Value Per Share--0.0540.0540%0.075-28%0.068-21%0.071-23%
Usd Dividend Per Share----0%-0%0.014-100%0.007-100%
Usd Eps---0.024-0.0240%-0.025+3%-0.025+3%-0.022-11%
Usd Free Cash Flow---9091114.200-9091114.2000%-8991557.700-1%-8319840.360-8%-8680427.580-5%
Usd Free Cash Flow Per Share---0.022-0.0220%-0.022-1%-0.020-8%-0.021-5%
Usd Free Cash Flow To Equity Per Share---0.023-0.0230%-0.017-27%-0.005-78%-0.005-77%
Usd Market Cap33081741.145-148%82042718.04082042718.0400%195843907.580-58%266241852.737-69%235012689.096-65%
Usd Price Per Share0.080-148%0.1990.1990%0.475-58%0.646-69%0.570-65%
Usd Profit---10044287.400-10044287.4000%-10375714.200+3%-10159772.940+1%-8827385.820-12%
Usd Revenue--1887719.7001887719.7000%3007248.600-37%2197051.380-14%1850402.070+2%
Usd Total Gains Per Share---0.021-0.0210%-0.022+2%0.009-344%0.005-486%
 EOD+3 -5MRQTTM+0 -0YOY+10 -245Y+10 -2610Y+7 -29

4.2. Fundamental Score

Let's check the fundamental score of Starpharma Holdings Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.294
Price to Book Ratio (EOD)Between0-11.479
Net Profit Margin (MRQ)Greater than0-5.321
Operating Margin (MRQ)Greater than0-8.395
Quick Ratio (MRQ)Greater than13.000
Current Ratio (MRQ)Greater than13.256
Debt to Asset Ratio (MRQ)Less than10.332
Debt to Equity Ratio (MRQ)Less than10.496
Return on Equity (MRQ)Greater than0.15-0.449
Return on Assets (MRQ)Greater than0.05-0.300
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Starpharma Holdings Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.803
Ma 20Greater thanMa 500.131
Ma 50Greater thanMa 1000.133
Ma 100Greater thanMa 2000.143
OpenGreater thanClose0.125
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets52,086
Total Liabilities17,271
Total Stockholder Equity34,815
 As reported
Total Liabilities 17,271
Total Stockholder Equity+ 34,815
Total Assets = 52,086

Assets

Total Assets52,086
Total Current Assets47,122
Long-term Assets4,964
Total Current Assets
Cash And Cash Equivalents 35,180
Net Receivables 8,235
Inventory 2,773
Other Current Assets 934
Total Current Assets  (as reported)47,122
Total Current Assets  (calculated)47,122
+/- 0
Long-term Assets
Property Plant Equipment 4,964
Other Assets 0
Long-term Assets  (as reported)4,964
Long-term Assets  (calculated)4,964
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities14,473
Long-term Liabilities2,798
Total Stockholder Equity34,815
Total Current Liabilities
Short-term Debt 5,522
Short Long Term Debt 4,778
Accounts payable 6,615
Other Current Liabilities 2,333
Total Current Liabilities  (as reported)14,473
Total Current Liabilities  (calculated)19,248
+/- 4,775
Long-term Liabilities
Long term Debt Total 2,750
Other Liabilities 48
Long-term Liabilities  (as reported)2,798
Long-term Liabilities  (calculated)2,798
+/-0
Total Stockholder Equity
Common Stock240,715
Retained Earnings -234,199
Accumulated Other Comprehensive Income 28,299
Total Stockholder Equity (as reported)34,815
Total Stockholder Equity (calculated)34,815
+/-0
Other
Capital Stock240,715
Cash And Equivalents33,519
Cash and Short Term Investments 35,180
Common Stock Shares Outstanding 409,035
Current Deferred Revenue3
Liabilities and Stockholders Equity 52,086
Net Debt -26,908
Net Invested Capital 39,593
Net Tangible Assets 34,815
Net Working Capital 32,649
Property Plant and Equipment Gross 8,092
Short Long Term Debt Total 8,272



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-30
> Total Assets 
0
0
29,053
26,025
18,859
10,715
18,491
12,500
25,013
30,423
24,653
28,847
37,567
29,807
54,268
48,550
36,862
44,383
59,039
66,591
58,511
48,859
39,078
73,238
66,175
52,086
52,08666,17573,23839,07848,85958,51166,59159,03944,38336,86248,55054,26829,80737,56728,84724,65330,42325,01312,50018,49110,71518,85926,02529,05300
   > Total Current Assets 
0
0
28,936
25,789
17,838
8,459
16,242
8,354
17,108
11,408
9,255
13,176
24,230
19,941
44,865
39,332
28,598
35,080
50,276
65,678
57,453
47,809
36,676
70,755
60,658
47,122
47,12260,65870,75536,67647,80957,45365,67850,27635,08028,59839,33244,86519,94124,23013,1769,25511,40817,1088,35416,2428,45917,83825,78928,93600
       Cash And Cash Equivalents 
0
0
28,079
25,412
17,434
7,892
15,658
8,166
14,284
10,073
7,482
11,595
22,851
18,918
42,812
33,840
24,028
30,848
45,972
61,188
51,319
41,251
30,054
60,500
49,918
35,180
35,18049,91860,50030,05441,25151,31961,18845,97230,84824,02833,84042,81218,91822,85111,5957,48210,07314,2848,16615,6587,89217,43425,41228,07900
       Net Receivables 
0
0
698
305
150
420
471
43
2,664
899
1,403
1,481
1,323
870
1,917
5,314
4,416
4,011
4,126
4,206
6,097
6,080
6,087
8,439
7,836
8,235
8,2357,8368,4396,0876,0806,0974,2064,1264,0114,4165,3141,9178701,3231,4811,4038992,6644347142015030569800
       Other Current Assets 
0
0
158
72
253
148
113
145
160
436
370
100
56
153
136
178
154
221
178
284
37
79
41
95
80
934
9348095417937284178221154178136153561003704361601451131482537215800
   > Long-term Assets 
0
0
117
236
1,022
2,256
2,248
4,146
7,905
19,016
15,398
15,671
13,337
9,866
9,403
9,218
8,264
9,303
8,763
913
1,058
1,050
2,402
2,483
5,517
4,964
4,9645,5172,4832,4021,0501,0589138,7639,3038,2649,2189,4039,86613,33715,67115,39819,0167,9054,1462,2482,2561,02223611700
       Property Plant Equipment 
0
0
117
236
1,022
2,005
1,556
1,233
1,431
1,111
758
447
219
280
414
411
509
910
690
913
1,058
1,050
2,402
2,483
5,517
4,964
4,9645,5172,4832,4021,0501,0589136909105094114142802194477581,1111,4311,2331,5562,0051,02223611700
       Goodwill 
0
0
0
0
0
0
0
0
0
1,755
1,547
1,835
1,747
1,387
1,461
1,606
1,581
1,939
2,005
0
0
0
0
0
0
0
00000002,0051,9391,5811,6061,4611,3871,7471,8351,5471,755000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
4,087
16,031
13,093
13,389
11,371
8,199
7,528
7,201
6,174
6,454
6,068
0
0
0
0
0
0
0
00000006,0686,4546,1747,2017,5288,19911,37113,38913,09316,0314,08700000000
       Other Assets 
0
0
0
0
74
0
0
0
0
43
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000430000740000
> Total Liabilities 
0
0
199
1,110
1,593
1,472
898
2,534
3,697
4,699
4,270
3,348
2,723
2,114
5,617
2,582
3,911
6,825
9,615
5,607
5,234
6,464
7,752
10,938
17,782
17,271
17,27117,78210,9387,7526,4645,2345,6079,6156,8253,9112,5825,6172,1142,7233,3484,2704,6993,6972,5348981,4721,5931,11019900
   > Total Current Liabilities 
0
0
199
1,110
1,593
1,269
755
2,365
3,033
3,260
3,715
3,143
2,665
2,041
5,435
2,459
3,844
6,769
9,575
5,521
5,164
6,426
6,697
10,429
10,231
14,473
14,47310,23110,4296,6976,4265,1645,5219,5756,7693,8442,4595,4352,0412,6653,1433,7153,2603,0332,3657551,2691,5931,11019900
       Short-term Debt 
0
0
0
0
0
60
60
60
142
69
124
133
160
49
40
25
27
30
18
23
26
26
604
692
695
5,522
5,5226956926042626231830272540491601331246914260606000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75
48
18
70
49
0
0
0
0
4,778
4,778000049701848750000000000000000
       Accounts payable 
0
0
160
1,016
1,208
670
429
1,647
1,898
1,855
1,623
1,764
1,346
940
4,156
1,208
2,586
5,481
8,210
4,034
3,023
4,098
4,394
6,711
6,762
6,615
6,6156,7626,7114,3944,0983,0234,0348,2105,4812,5861,2084,1569401,3461,7641,6231,8551,8981,6474296701,2081,01616000
       Other Current Liabilities 
0
0
39
93
214
257
266
280
331
356
417
316
530
703
842
1,115
1,187
1,184
1,347
1,453
1,708
1,875
1,262
2,614
2,308
2,333
2,3332,3082,6141,2621,8751,7081,4531,3471,1841,1871,115842703530316417356331280266257214933900
   > Long-term Liabilities 
0
0
0
0
0
204
144
169
664
1,440
555
205
58
73
182
123
67
56
40
86
70
38
1,055
509
7,551
2,798
2,7987,5515091,05538708640566712318273582055551,44066416914420400000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
0
47
23
0
970
475
7,494
2,750
2,7507,4944759700234701800000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
89
349
226
134
45
58
56
82
48
19
38
40
39
47
38
85
34
57
48
485734853847394038194882565845134226349890000000
> Total Stockholder Equity
0
0
28,853
24,916
17,010
9,243
17,592
9,966
21,316
25,724
20,383
25,499
34,844
27,693
48,651
45,968
32,951
37,558
49,424
60,984
53,277
42,395
31,326
62,300
48,393
34,815
34,81548,39362,30031,32642,39553,27760,98449,42437,55832,95145,96848,65127,69334,84425,49920,38325,72421,3169,96617,5929,24317,01024,91628,85300
   Common Stock
0
0
33,065
33,034
33,034
33,034
46,822
46,822
65,375
76,227
78,667
85,640
101,766
105,399
139,171
140,081
140,349
160,884
193,512
193,549
193,583
193,621
193,661
240,630
240,669
240,715
240,715240,669240,630193,661193,621193,583193,549193,512160,884140,349140,081139,171105,399101,76685,64078,66776,22765,37546,82246,82233,03433,03433,03433,06500
   Retained Earnings Total Equity00000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-23
-86
-259
-47
13
-28
497
1,299
1,009
3,279
2,876
1,022
1,866
3,502
4,852
7,874
9,787
10,896
13,440
16,775
20,340
24,077
26,285
28,299
28,29926,28524,07720,34016,77513,44010,8969,7877,8744,8523,5021,8661,0222,8763,2791,0091,299497-2813-47-259-86-2300
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
0
23
86
259
0
0
0
0
0
0
0
0
0
0
0
4,852
-1,385
-1,118
10,896
13,440
16,775
-10,986
-38,223
-22,108
-6,516
-6,516-22,108-38,223-10,98616,77513,44010,896-1,118-1,3854,85200000000000259862300



Balance Sheet

Currency in AUD. All numbers in thousands.